NCT03288454View on ClinicalTrials.gov

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions
Healthy
Interventions
DRUG

Ciraparantag

Ciraparantag (administered over 10 minutes)

DRUG

Placebo

Saline for injection

DRUG

Apixaban

Apixaban 10mg given twice daily (q12h)

Trial Locations (1)

07094

Frontage Clinical Services Inc., Secaucus

All Listed Sponsors
lead

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

INDUSTRY

NCT03288454 - Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT | Biotech Hunter | Biotech Hunter